NCT04676867

Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 227 (actual)
• Sponsor: DalCor Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a placebo-controlled, Phase 2a proof-of-concept clinical study which will evaluate efficacy and safety of dalcetrapib in outpatients patients with mild to moderate, symptomatic, confirmed COVID 19.

Conditions

• Covid19

Interventions

Type	Name	Description
DRUG	Dalcetrapib	Dalcetrapib 300 mg Film-Coated Tablets
OTHER	Placebo	Placebo Tablets

Timeline

• Start date: 2021-01-11
• Primary completion: 2021-05-17
• Completion: 2021-05-17
• First posted: 2020-12-21
• Last updated: 2022-12-07
• Results posted: 2022-12-07

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study